Drugs / CEP-40783
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03454243 | Feb → Jun 2018 | — | Hoffmann-La Roche | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CEP-40783 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650515 ↗ |
| Known as | RXDX-106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03454243 ↗ |
| Action | Inhibit | “TYRO3, AXL, and MER (TAM) Tyrosine Kinase Inhibitor” NCT03454243 ↗ |
| Modality | Small molecule | “Oral Immunomodulatory TYRO3, AXL, and MER (TAM) Tyrosine Kinase Inhibitor” NCT03454243 ↗ |
| Route | Oral | “continuous daily oral doses of RXDX-106” NCT03454243 ↗ |
| Target | AXL | “TYRO3, AXL, and MER (TAM) Tyrosine Kinase Inhibitor” NCT03454243 ↗ |
| Target | TYRO3 | “TYRO3, AXL, and MER (TAM) Tyrosine Kinase Inhibitor” NCT03454243 ↗ |